Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeneDx Holdings Corp.'s filings document financial results and operating disclosures for a genomics diagnostics company focused on rare disease testing. Form 8-K reports furnish quarterly and annual results, earnings presentations, preliminary revenue and testing-volume guidance, changes in statement presentation, and modifications to non-GAAP financial measure methodology.
The filing record also covers capital structure and governance matters, including a term loan agreement used to refinance existing debt, Class A common stock and Nasdaq-listed warrant disclosures, board composition changes, and definitive proxy materials. Proxy filings describe director elections, executive compensation, equity awards, stockholder voting matters, and related corporate governance policies.
GeneDx Holdings Corp. reported that Chief Executive Officer Katherine Stueland acquired additional company stock. On March 6, 2026, she obtained 3,404 shares of GeneDx Class A common stock directly from the company in an exempt transaction at $88.11 per share, based on that day’s closing price.
Following this acquisition, Stueland directly holds 42,087 shares of GeneDx Class A common stock. The transaction was executed under a Subscription Agreement between GeneDx and Stueland and was structured to qualify for exemption under Rule 16b-3(d).
GeneDx Holdings Corp. reported that investment funds advised by Corvex Management LP, with Keith A. Meister as a control person, made open-market purchases of a total of 169,521 shares of Class A common stock on March 3 and March 5 at prices generally ranging from about $70 to $82 per share.
After these trades, investment funds advised by Corvex directly held 3,228,150 GeneDx Class A shares. CMLS Holdings LLC held 333,144 shares, over which Mr. Meister shares voting and investment discretion, and Mr. Meister’s beneficial holdings also include 20,129 shares issued upon vesting of restricted stock units for his board service. Corvex and Mr. Meister each disclaim beneficial ownership except to the extent of their pecuniary interest.
GeneDx Holdings Corp. reported that Chief Operating Officer Bryan Dechairo acquired 10,430 restricted stock units (RSUs) as an equity award. Each RSU represents a contingent right to receive one share of Class A common stock for no cash consideration upon settlement.
The award vests over time, with 25% of the RSUs vesting each year on the anniversary of the grant date. The first tranche is scheduled to vest on April 1, 2027, provided Dechairo continues to serve the company on each vesting date. The RSUs have no expiration; they either vest or are cancelled before vesting.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported a mix of equity awards and share sales. On March 3, 2026, he acquired 15,262 shares of Class A Common Stock and 10,865 RSUs at no cost in connection with a performance-based restricted stock unit award tied to revenue and adjusted net income.
On March 4, 2026, he sold a total of 6,187 shares of Class A Common Stock in open-market transactions at weighted average prices in the high-$70 range to cover tax withholding obligations from that vesting. After these transactions, he beneficially owned 18,674 shares, plus RSUs for up to 122,897 shares and options for up to 25,906 shares, subject to vesting.
GeneDx Holdings Corp. chief executive officer Katherine Stueland reported a mix of equity awards and related share sales. On March 3, 2026, she acquired 47,684 shares of Class A Common Stock and 40,418 restricted stock units as a grant tied to a 2025 performance-based award.
On March 4, 2026, she sold a total of 25,459 shares of Class A Common Stock in open-market transactions at weighted average prices between about $77 and $79.64 per share to cover tax withholding obligations from the award’s vesting. After these transactions, she directly owned 38,683 shares, plus RSUs for up to 451,912 shares and options for up to 107,610 shares, all subject to their vesting terms.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported both an RSU vesting and a small tax-related stock sale. On March 1, 2026, 718 restricted stock units were settled, converting into 718 shares of Class A common stock for no cash cost.
On March 2, 2026, Feeley sold 287 Class A shares in an open-market transaction solely to cover tax withholding from the RSU vesting, at a weighted average price of $77.5187 per share, with individual trades ranging from $76.99 to $77.53. After these transactions, he beneficially owned 9,599 Class A shares, RSUs representing up to 112,032 additional shares, and options to purchase up to 25,906 shares, which vest quarterly at 6.25% of the total award.
GeneDx Holdings Corp. entered into a new Loan Agreement with Blackstone-affiliated lenders providing a $100.0 million term loan funded at closing. The company used the proceeds to repay its prior term loan and plans to direct remaining funds toward balance sheet initiatives, potential reductions of certain operating obligations, and general corporate purposes.
The Term Loan bears interest at Term SOFR plus 4.50%, with a 1.50% SOFR floor, and matures five years from the closing date. It is secured by a first lien on substantially all assets of GeneDx and its guarantor subsidiaries and includes a minimum liquidity covenant of $50 million, mandatory prepayments upon specified events, and optional prepayment subject to yield protection premiums.
GeneDx Holdings Corp. files its annual report describing a genomics business built around exome and whole genome sequencing, including ExomeDx™ and GenomeDx™ tests that hold FDA Breakthrough Device Designation. The company emphasizes one of the world’s largest rare disease datasets, with over 2.5 million tests, including more than 1 million exomes and genomes, and a high proportion of non‑European samples.
Growth priorities focus on pediatric outpatient genetics, NICU rapid genomes, prenatal testing and genomic newborn screening through studies such as GUARDIAN, BEACONS and SeqFirst, plus international expansion via the 2025 Fabric Genomics acquisition. The report details a heavily regulated environment, reimbursement dependence, intense competition, extensive use of AI for interpretation, and broad U.S. and international privacy, laboratory, and fraud‑and‑abuse compliance obligations.
GeneDx Holdings Corp. reported strong growth for 2025, with revenue rising to $427.5 million, up 41% year over year, and exome and genome test revenue reaching $360.3 million, up 54%. Adjusted gross margin improved to 71% and adjusted net income increased to $41.8 million from $9.4 million in 2024, while GAAP net loss narrowed to $21.0 million.
Fourth-quarter 2025 revenue was $121.0 million, including $104.0 million from exome and genome testing, with test volumes up 34.3% to 27,761. The company ended the year with $172.3 million in cash, cash equivalents, marketable securities and restricted cash and reaffirmed 2026 guidance for revenue of $540–$555 million, 33–35% exome and genome growth, adjusted gross margin of at least 70%, and positive adjusted net income.
GeneDx Holdings Corp.'s Chief Operating Officer, Dechairo Bryan, reported multiple open‑market sales of Class A Common Stock on February 4, 2026 under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 15, 2025.
The transactions totaled 5,961 shares sold at weighted average prices ranging from $83.0352 to $91.92 per share, reducing his directly held Class A Common Stock to zero. After these sales, he beneficially owned RSUs covering contingent rights to receive up to 28,123 shares of Class A Common Stock, vesting according to their terms.